Skip to main content

Table 1 Demographic and clinical characteristics of the two groups

From: Can the prophylactic quadrivalent HPV vaccine be used as a therapeutic agent in women with CIN? A randomized trial

VariableControl group (N = 104)HPV vaccine group (N = 138)P value
Age, (y)
 Min- Max22–4122–42 
 Mean ± SD33.04 ± 4.631.7 ± 4.80.5*
Marital status; N (%)
 Married103 (99)136 (98.5) 
 Divorced1 (1)2 (1.45)0.8**
CIN 1; N (%)35 (33.7)45 (32.6) 
CIN 2; N (%)35 (33.7)50 (36.2)0.3***
CIN 3; N (%)34 (32.6)43 (31.2) 
Two-dose vaccination; N (%)35 (26.4)
Three-dose vaccination; N (%)103 (74.6) 
  1. Abbreviations: Y year; N number; CIN Cervical intraepithelial neoplasia; SD Standard deviation, *Student’s t test, ** Fisher’s exact test, ***Chi-squared test